Logo

Samsung Bioepis Reports Results of Renflexis (biosimilar- infliximab) from Two Studies in IBD Patients

Share this

Samsung Bioepis Reports Results of Renflexis (biosimilar- infliximab) from Two Studies in IBD Patients

Shots:

  • The company reported results from two real-world studies of Renflexis (infliximab-abda) in patients with IBD registered in the US Veteran Affairs Healthcare System database. Data were presented at ACG 2020
  • One study assesses the safety of switching from reference infliximab or infliximab-dyyb to Renflexis in patients with IBD identified from the VAHS database and demonstrated an 83% continuation rate over 1yr. with similar continuation rate in patients who underwent a single & double switch from reference infliximab
  • Second study focused on the real-world utilization pattern of infliximab products for IBD- within the context of VANF policy. The study found that Renflexis became the preferred infliximab product on VANF in Sept’2018 which was faster than the adoption of the previous biosimilar (infliximab-dyyb)- listed on VANF in May’2017

 ­ Ref: GlobeNewswire | Image: Samsung Bioepis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions